Chronic lymphocytic leukemia (CLL) patients with high proliferation features have upregulated OXPHOS and the mTOR pathway.457 Venetoclax, a BCL-2 inhibitor, is used in CLL treatment. Here, MTOR is linked to B-cell chronic lymphocytic leukemia.